CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis
| Autor: | Benjamine Geeraert, Alain Géloën, Eric Malaud, Paul Holvoet, Lionel Helin, Gérard Marguerie |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
CD36 Antigens
Male CD36 Glycobiology Biochemistry Mice Biomacromolecule-Ligand Interactions chemistry.chemical_classification Hypertriglyceridemia Multidisciplinary biology Fatty Acids Postprandial Period Lipids Postprandial Medicine Research Article medicine.medical_specialty Science Thiophenes Cell Line Diabetes Complications Insulin resistance Internal medicine Diabetes mellitus Chemical Biology medicine Animals Humans Scavenger receptor Rats Wistar Biology Bioinorganic Chemistry Glycoproteins Dyslipidemias Fatty acid Biological Transport Lipid Aggregates medicine.disease Lipid Metabolism Atherosclerosis Rats Disease Models Animal Endocrinology Metabolism chemistry biology.protein Benzimidazoles Metabolic syndrome Insulin Resistance |
| Zdroj: | PLoS ONE, Vol 7, Iss 5, p e37633 (2012) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane associated molecules in different cells and tissues have however questioned its potential as a therapeutic target. The present study shows that it is possible to identify low molecular weight chemicals that can block the CD36 binding and uptake functions. These inhibitors were able to reduce arterial lipid deposition, fatty acid intestinal transit, plasma concentration of triglycerides and glucose, to improve insulin sensitivity, glucose tolerance and to reduce the plasma concentration of HbAc1 in different and independent rodent models. Correlation between the anti-CD36 activity of these inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and diabetes were observed at pharmacological doses. Thus, CD36 might represent an attractive therapeutic target. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|